Ekso Bionics Holdings, Inc.

Hello, and welcome to the Exobionics Q2 2022 Financial Results Conference Call. At this time, all participants are in listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to David Carey. Please go ahead.

Thank you, operator, and thank you all for participating in today's call. Joining me from Exobionics are Stephen Chairman, Chairman and Chief Executive Officer, Scott Davis, President and Chief Operating Officer, and Jerome Wong, Interim Chief Financial Officer. Earlier today, Exobionics released financial results for the second quarter of 2022. A copy of the press release is available on the company's website. Before we begin, I would like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be deemed to be forward-looking statements. All forward-looking statements, including statements regarding our business strategy, future financial or operational expectations, or our expectations of the regulatory landscape governing our products and operations, are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. Exodus claims any intention or obligation except as required by law to update or revise any financial or operational projections, a regulatory outlook, or other forward-looking statements, whether because of new information, future events, or otherwise, which speak only as of today, July 28, 2022. I will now turn the call over to ExoBionics Chairman and CEO, Stephen Sherman.

Thank you, David, and thank you to everyone for joining us today. We achieved strong revenue growth in the second quarter, reflecting the continued execution by our team. We are successfully raising awareness of the benefits that our innovative XONR devices are bringing to patients. This is resulting in strong demand with inpatient rehabilitation facilities and network operators. And now with the recent clearance by the US Food and Drug Administration, giving us the ability to market XONR With use with MS patients, we are poised to help a significantly larger patient population. Our ExoWorks business continues to build momentum with large key customers as they more clearly understand the overhead productivity and safety benefits that our Exo EVO devices deliver. We expect this segment to be a significant contributor to our growth in the future. Financially, we are in a solid cash position. Our dedicated team of professionals are constantly improving efficiencies. Our commercial team is deepening customer relationships, and management team is motivated by our core responsibility, which is to maximize shareholder value. Now I will turn the call over to our President and Chief Operating Officer, Scott Davis.